Antiphospholipid antibody testing.

Anti-beta-2 glycoprotein I antibodies Anticardiolipin antibodies Anticoagulante lúpico Anticuerpo antifosfolípido Anticuerpos anti-beta-2 glicoproteína I Anticuerpos anticardiolipina Antiphospholipid antibody Antiphospholipid antibody testing Lupus anticoagulant Pruebas de anticuerpos antifosfolípidos

Journal

Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 18 01 2024
revised: 19 06 2024
accepted: 26 06 2024
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 22 8 2024
Statut: ppublish

Résumé

Antiphospholipid antibodies (aPL) are a family of autoantibodies targeting phospholipid-binding proteins and are associated with several clinical settings, and most notably define the antiphospholipid syndrome (APS). These antibodies can be identified using a variety of laboratory tests, which include both solid-phase immunological assays and functional clotting assays that detect lupus anticoagulants (LA). aPLs are linked to a range of adverse medical conditions, such as thrombosis and complications affecting the placenta and fetus, potentially leading to morbidity and mortality. The specific aPL identified, along with the pattern of reactivity, correlates with the severity of these conditions. Therefore, laboratory testing for aPL is crucial for evaluating the risk of complications and for fulfilling certain classification criteria for APS, which are also applied as diagnostic markers in medical practice. This review provides an overview of the available laboratory tests currently for measuring aPL and discusses their clinical implications.

Identifiants

pubmed: 39174152
pii: S0025-7753(24)00433-0
doi: 10.1016/j.medcli.2024.06.002
pii:
doi:

Substances chimiques

Antibodies, Antiphospholipid 0
Lupus Coagulation Inhibitor 0
Biomarkers 0

Types de publication

Journal Article Review

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

S4-S9

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Savino Sciascia (S)

University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. Electronic address: savino.sciascia@unito.it.

Barbara Montaruli (B)

S.C. Laboratory Analysis, AO Ordine Mauriziano, Turin, Italy.

Maria Infantino (M)

Laboratory of Immunology and Allergy, San Giovanni di Dio Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH